Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

5.690 +0.160 (+2.89%)

Streaming Delayed Price Updated: 12:41 PM EDT, Mar 11, 2026 Add to My Watchlist

Price and Volume

Volume	201,146
Open	5.770
Bid (Size)	5.680 (200)
Ask (Size)	5.700 (400)
Prev. Close	5.530
Today's Range	5.635 - 6.000
52wk Range	1.730 - 11.41
Shares Outstanding	30,674,855
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Today 7:30 EDT

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

February 25, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Performance

YTD	-5.0%	-5.0%
1 Month	+4.4%	+4.4%
3 Month	-9.4%	-9.4%
6 Month	-17.4%	-17.4%
1 Year	+60.7%	+60.7%

More News

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

February 05, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Tuesday's session: gap up and gap down stocks ↗

February 03, 2026

Via Chartmill

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study ↗

October 24, 2025

Via Stocktwits

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

February 02, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

January 08, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

December 18, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

December 17, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration

December 10, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 09, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

November 20, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

November 10, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

October 22, 2025

Via Benzinga

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

October 14, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

October 07, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

October 01, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

September 24, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

September 17, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

September 10, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

August 26, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Tops Q2 EPS Forecast ↗

August 13, 2025

Via The Motley Fool

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?

Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.

What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?

Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?

The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market

What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?

The current price of Sagimet Biosciences Inc. - Series A Common Stock is 5.690

When was Sagimet Biosciences Inc. - Series A Common Stock last traded?

The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 03/11/26 12:41 PM ET

What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?

The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 174.54M

How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?

Sagimet Biosciences Inc. - Series A Common Stock has 175M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.